Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2016
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 24 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
- 24 Aug 2016 Status changed from active, no longer recruiting to recruiting.
- 17 Jul 2015 New trial record